Factors affecting the prognosis of breast cancer patients with brain metastases

Breast

Volumn 17, Issue 5, 2008, Pages 451-458

  Saip, Pinar ^a   Cicin, Irfan ^b   Eralp, Yesim ^a   Kucucuk, Seden ^a   Tuzlali, Sitki ^a   Karagol, Hakan ^b   Aslay, Isik ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY   (Turkey)

Author keywords

Brain metastasis; Breast cancer; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GAMMA KNIFE RADIOSURGERY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TIME; TUMOR VOLUME;

EID: 53149144684     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.03.004     Document Type: Article

References (31)

1. DiStefano A., Yong Yap Y., Hortobagyi G.N., and Blumenschein G.R. The natural history of breast cancer patients with brain metastases. Cancer 44 (1979) 1913-1918
2. Lin N.U., Bellon J.R., and Winer E.P. CNS metastases in breast cancer. J Clin Oncol 22 (2004) 3608-3617
3. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
4. Shmueli E., Wigler N., and Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40 (2004) 379-382
5. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., and Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4 (2003) 114-119
6. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (2004) 639-643
7. Tham Y.L., Sexton K., Kramer R., Hilsenbeck S., and Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107 (2006) 696-704
8. Samaan N.A., Buzdar A.U., Aldinger K.A., Schultz P.N., Yang K.P., Romsdahl M.M., et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 47 (1981) 554-560
9. Gonzalez-Angulo A.M., Cristofanilli M., Strom E.A., Buzdar A.U., Kau S.W., Broglio K.R., et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101 (2004) 1760-1766
10. Miller K.D., Weathers T., Haney L.G., Timmerman R., Dickler M., Shen J., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14 (2003) 1072-1077
11. Ryberg M., Nielsen D., Osterlind K., Andersen P.K., Skovsgaard T., and Dombernowsky P. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 91 (2005) 217-225
12. Gabos Z., Sinha R., Hanson J., Chauhan N., Hugh J., Mackey J.R., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 (2006) 5658-5663
13. Palmieri D., Bronder J.L., Herring J.M., Yoneda T., Weil R.J., Stark A.M., et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67 (2007) 4190-4198
14. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., and Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16 (2005) 1772-1777
15. llis I.O., Bartlettt J., Dowswett M., Humphreys S., Basani B., Miller K., et al. Updated recommendations for her-2 testing in the UK. J Clin Pathol 57 (2004) 233-237
16. Pierga J.Y., Asselain B., Jouve M., Diéras V., Carton M., Laurence V., et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 91 (2001) 1079-1089
17. Paterson A.H., Agarwal M., Lees A., Hanson J., and Szafran O. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49 (1982) 651-654
18. Crivellari D., Pagani O., Veronesi A., Lombardi D., Nolè F., Thürlimann B., Hess D., et al. International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12 (2001) 353-356
19. Pestalozzi B.C., Francis P., Quinaux E., Dolci S., Gelber R., Lang I., et al. Is risk of CNS-relapse related to adjuvant taxane treatment in node-positive breast cancer patients? First results of the CNS-substudy in the intergroup phase III BIG 02-98 trial. Breast Cancer Res and Treat (SABCS) Suppl 1 (2006) a2082
20. Carey L.A., Ewend M.G., Metzger R., Sawyer L., Dees E.C., Sartor C.I., et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 88 (2004) 273-280
21. Gori S., Rimondini S., De Angelis V., Colozza M., Bisagni G., Moretti G., et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12 (2007) 766-773
22. Henry S., Pierga J.Y., Asselah J., Cottu P., Mignot L., Sigal-Zafrani B., et al. Brain metastasis in HER2+ metastatic breast cancer patients: analysis of prognostic factors. Breast Cancer Res and Treat (SABCS) Suppl 1 (2007) a6017
23. Weitzen R., Zach L., Kaufman B., Tichler T., Rath P., and Pfeffer R. High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 21 (2002) 316 (abstr 1936)
24. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial-EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Ins 88 (1996) 890-899
25. Aupérin A., Arriagada R., Pignon J.P., Le Péchoux C., Gregor A., Stephens R.J., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341 (1999) 476-484
26. Lin N.U., and Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 13 (2007) 1648-1655
27. Christodoulou C., Bafaloukos D., Kosmidis P., Samantas E., Bamias A., Papakostas P., et al. Hellenic Cooperative Oncology Group. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12 (2001) 249-254
28. Trudeau M.E., Crump M., Charpentier D., Yelle L., Bordeleau L., Matthews S., et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17 (2006) 952-956
29. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
30. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Bullitt E., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol (ASCO) 24 Suppl 18 (2006) a503
31. Moy B., and Goss P.E. Lapatinib: current status and future directions in breast cancer. Oncologist 11 (2006) 1047-1057